Gaudium IVF and Women Health IPO
ClosedAlready have an account? Apply now
Gaudium IVF and Women Health IPO details
Schedule of Gaudium IVF and Women Health
| Issue open date | 20 Feb 2026 |
| Issue close date | 24 Feb 2026 |
| UPI mandate deadline | 24 Feb 2026 (5 PM) |
| Allotment finalization | 25 Feb 2026 |
| Refund initiation | 26 Feb 2026 |
| Share credit | 26 Feb 2026 |
| Listing date | 27 Feb 2026 |
| Mandate end date | 11 Mar 2026 |
| Lock-in end date for anchor investors (50%) | 27 Mar 2026 |
| Lock-in end date for anchor investors (remaining) | 26 May 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Gaudium IVF and Women Health
Gaudium IVF and Women Health Limited is a public limited company incorporated on March 24, 2015, originally as Gaudium IVF and Women Health Private Limited. The Company was converted into a public limited entity on October 24, 2024. Its registered office is located in Janak Puri, New Delhi, India. The Company was founded by its Promoter, Dr Manika Khanna, and is promoted by Dr Manika Khanna, Dr Peeyush Khanna and Vishad Khanna. Gaudium IVF operates in the assisted reproductive technology (ART) segment, providing fertility treatments such as In Vitro Fertilisation (IVF), Intracytoplasmic Sperm Injection (ICSI), and Intrauterine Insemination (IUI). It has expanded across multiple states through a hub-and-spoke model and operates 30+ locations, comprising 7 hubs and 28 spokes. Its business model focuses on specialised fertility services delivered through standardised clinical protocols and stage-wise treatment processes. The Company’s strengths include strong promoter-led clinical expertise, an expanding multi-location network, and its positioning within India’s growing IVF and fertility services market.
Financials of Gaudium IVF and Women Health
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 165 |
| Fresh Issue – Proceeds go to the company | 90 |
| Offer for sale – Proceeds go to the existing investors | 75 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Establishment of New IVF Centers (Capital Expenditure) | 50 (55.56%) |
| Repayment / Pre-payment of Outstanding Loans | 20 (22.22%) |
| General corporate purposes | 20 (22.22%) |
Strengths
- Established IVF-focused brand founded by experienced specialist Dr. Manika Khanna.
- Pan-India presence with 30+ locations under a scalable hub-and-spoke model.
- Comprehensive fertility portfolio including IVF, ICSI and IUI treatments.
- Strong revenue growth and improving profitability in recent years.
- Positioned in a fast-growing Indian IVF market with high projected growth.
Risks
- High contingent liabilities relative to net worth.
- Exposure to operational and legal risks inherent in healthcare services.
- High employee attrition and dependence on skilled doctors and embryologists.
- Significant dependence on promoters for leadership and brand value.
- Past negative cash flows and rising borrowings are impacting financial flexibility
Allotment Status for Gaudium IVF and Women Health
To check your IPO allotment status:
- Visit the Bigshare Services IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status
Subscription Figures for Gaudium IVF and Women Health
As per media reports (Link), the Grey Market Premium (GMP) of Gaudium IVF and Women Health is reported at ₹5 over the IPO price. This metric is unreliable; to track IPO interest, it is better to check subscription numbers published by exchanges, which are considered more reliable indicators.
Subscription numbers as of 05:00 PM on February 24, 2026:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 41.77 | 67.85 | 1.62x |
| NII | 31.33 | 440.22 | 14.05x |
| Retail | 73.10 | 555.24 | 7.60x |
| Total | 146.20 | 1063.31 | 7.27x |